Insider Transactions in Q1 2021 at Neurocrine Biosciences Inc (NBIX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
SELL
Open market or private sale
|
Direct |
1,700
-2.54%
|
$202,300
$119.95 P/Share
|
|
Feb 10
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+2.47%
|
$59,500
$35.99 P/Share
|
|
Feb 09
2021
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
36,194
-20.68%
|
$4,198,504
$116.64 P/Share
|
|
Feb 09
2021
|
Darin Lippoldt Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,194
+15.09%
|
$1,266,790
$35.99 P/Share
|
|
Feb 08
2021
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,363
-6.05%
|
$274,108
$116.75 P/Share
|
|
Feb 08
2021
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,910
-9.17%
|
$337,560
$116.83 P/Share
|
|
Feb 08
2021
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,407
-3.28%
|
$395,212
$116.72 P/Share
|
|
Feb 08
2021
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,466
-0.77%
|
$1,214,056
$116.75 P/Share
|
|
Feb 08
2021
|
Dimitri E. Grigoriadis Chief Research Officer |
SELL
Open market or private sale
|
Direct |
2,708
-1.06%
|
$314,128
$116.69 P/Share
|
|
Feb 08
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
SELL
Open market or private sale
|
Direct |
3,261
-3.32%
|
$378,276
$116.83 P/Share
|
|
Feb 08
2021
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,338
-4.71%
|
$155,208
$116.74 P/Share
|
|
Feb 08
2021
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,270
-6.67%
|
$495,320
$116.83 P/Share
|
|
Feb 08
2021
|
Haig P. Bozigian Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,842
-0.81%
|
$445,672
$116.81 P/Share
|
|
Feb 08
2021
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,693
-1.17%
|
$428,388
$116.85 P/Share
|
|
Feb 05
2021
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
605
-1.94%
|
$68,970
$114.05 P/Share
|
|
Feb 05
2021
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,422
-0.54%
|
$276,108
$114.16 P/Share
|
|
Feb 05
2021
|
Dimitri E. Grigoriadis Chief Research Officer |
SELL
Open market or private sale
|
Direct |
605
-0.73%
|
$68,365
$113.76 P/Share
|
|
Feb 05
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
SELL
Open market or private sale
|
Direct |
865
-2.83%
|
$98,610
$114.15 P/Share
|
|
Feb 05
2021
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
605
-4.75%
|
$68,365
$113.86 P/Share
|
|
Feb 05
2021
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
809
-4.69%
|
$92,226
$114.03 P/Share
|
|
Feb 05
2021
|
Haig P. Bozigian Chief Development Officer |
SELL
Open market or private sale
|
Direct |
704
-0.46%
|
$79,552
$113.79 P/Share
|
|
Feb 05
2021
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,677
-1.32%
|
$302,501
$113.93 P/Share
|
|
Jan 26
2021
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
400
-1.25%
|
$48,000
$120.0 P/Share
|
|
Jan 26
2021
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+1.83%
|
$12,300
$41.78 P/Share
|
|
Jan 26
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
SELL
Open market or private sale
|
Direct |
1,100
-1.86%
|
$130,900
$119.97 P/Share
|
|
Jan 26
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,100
+1.83%
|
$38,500
$35.99 P/Share
|
|
Jan 26
2021
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
400
-0.18%
|
$48,000
$120.0 P/Share
|
|
Jan 25
2021
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,077
-12.92%
|
$609,240
$120.03 P/Share
|
|
Jan 25
2021
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,477
+14.27%
|
$142,557
$41.78 P/Share
|
|
Jan 25
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
SELL
Open market or private sale
|
Direct |
17,570
-16.48%
|
$2,090,830
$119.97 P/Share
|
|
Jan 25
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,570
+13.99%
|
$597,380
$34.99 P/Share
|
|
Jan 25
2021
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
1,600
-0.71%
|
$192,000
$120.03 P/Share
|
|
Jan 08
2021
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
308,250
-25.87%
|
$33,907,500
$110.22 P/Share
|
|
Jan 08
2021
|
Kevin Charles Gorman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
308,250
+20.54%
|
$2,466,000
$8.66 P/Share
|
|
Jan 08
2021
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,632
-14.24%
|
$292,152
$111.06 P/Share
|